PUBLIC SUMMARY DOCUMENT

Product: Mediplast Australia Pty Ltd Wellspect HealthCare lleostomy/Koch
Applicant: Mediplast Australia Pty Ltd
Date of SPAP Meeting: 12 October 2021

1. Proposed Deletion on the Stoma Appliance Scheme

The applicant, Mediplast Australia Pty Ltd, sought the deletion of the entire product range of Mediplast Australia Pty Ltd Wellspect HealthCare lleostomy/Koch (SAS Code 9822Y) in subgroup 8(c) of the Stoma Appliance Scheme (the Scheme) Schedule, due to the product no longer being manufactured. The product is currently listed at a unit price of $7.25, with a maximum monthly quantity of two units.

2. Substitute products

Not Applicable.

Variant to be deleted

Product Code	Description
68730	Non sterile catheter for continent ileostomy & koch pouch patients.

3. Background

This product was first listed on the Scheme Schedule on 1 April 2011.

4. Clinical Place for the Product

Not Applicable.

Financial Analysis

The deletion of the entire product range is recommended. It is therefore, unlikely that there would be any budgetary impact for the Scheme as a consequence of deleting this product.

5. Panel Recommendation

The Panel recommended the deletion of the entire product range of Mediplast Australia Pty Ltd Wellspect HealthCare lleostomy/Koch (SAS Code 9822Y) in subgroup 8(c) of the Scheme Schedule at the unit price of $7.25, with a maximum monthly quantity of two units.

The Panel also noted that Mediplast Australia Pty Ltd is to advise Stoma Associations, ostomates, Stomal Therapy Nurses and ACSA of the deletion. A period of approximately six months from the date of the Panel's recommendation (12 October 2021) should be given to allow users of the product to seek a suitable alternative and to enable Stoma Associations to manage their stock levels.

6. Context for Decision

The Panel helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context.
A Panel decision not to recommend listing or changes to a listing does not represent a final Panel view about the merits of a particular stoma product. A company can resubmit to the Panel following a decision not to recommend listing or changes to a listing. The Panel is an advisory committee and as such its recommendations are non-binding on Government.
All Panel recommendations are subject to Cabinet/Ministerial approval.

7. Applicant's Comment

Mediplast notes the SPAP's recommendation.